Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 2228-2230

  Huang, Yanjie ^a   Carroll, Karen C ^b   Cosgrove, Sara E ^b   Tamma, Pranita D ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME SYNTHESIS; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEUS MIRABILIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; BACTERIUM; DRUG EFFECTS; ENZYMOLOGY; EVALUATION STUDY; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; CEFTRIAXONE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS;

EID: 84901659772     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00716-14     Document Type: Article

References (11)

1. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN, Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin. Infect. Dis. 56:1301-1309. http://dx.doi.org/10.1093/cid/cit017.
2. Marchaim D, Sunkara B, Lephart PR, Gudur UM, Bhargava A, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Chopra T, Dhar S, Kaye KS. 2012. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect. Control Hosp. Epidemiol. 33:853-855. http://dx.doi.org/10.1086/ 666632.
3. Perez F, Bonomo RA. 2012. Can we really use beta-lactam/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum beta-lactamase-producing bacteria? Clin. Infect. Dis. 54: 175-177. http://dx.doi.org/10.1093/cid/cir793.
4. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. 2013. Cefepime therapy for monomicrobial bacteremia caused by cefepimesusceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin. Infect. Dis. 56:488-495. http://dx.doi.org/10.1093/cid/cis916.
5. Hsu AJ, Tamma PD. 2014. The treatment of multi-drug resistant gramnegative infections in children. Clin. Infect Dis. http://dx.doi.org/10. 1093/cid/ciu069.
6. Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, Garcia C, Miguelañez S, Pérez-Vázquez García-Cobos S, Aracil B, Bautista V, Campos J. 2006. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J. Clin. Microbiol. 44:2359-2366. http://dx.doi.org/10.1128/JCM.00447-06. (Pubitemid 44092399)
7. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Tamma PD, Wu H, Gerber JS, Hsu AJ, Tekle T, Carroll KC, Cosgrove SE. 2013. Outcomes of children with Enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes? Pediatr. Infect. Dis. J. 32:965-969. http://dx.doi.org/10. 1097/INF.0b013e31829043b3.
9. Tamma PD, Powers JH. 2013. Do patient data really support the Clinical and Laboratory Standards Institute recommendation for lowering thirdgeneration cephalosporin interpretive breakpoints? Clin. Infect. Dis. 57: 624-625. http://dx.doi.org/10.1093/cid/cit308.
10. Tamma PD, Savard P, Pal T, Sonnevend A, Perl TM, Milstone AM. 2012. An outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. Infect. Control Hosp. Epidemiol. 33:631-634. http://dx.doi.org/10.1086/665715.
11. Tamma PD, Girdwood SCT, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. 2013. The use of cefepime for treating AmpC-lactamase-producing Enterobacteriaceae. Clin. Infect. Dis. 57: 781-788. http://dx.doi.org/10.1093/cid/cit395.